Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.25
NYSE:GSK's Cash-to-Debt is ranked lower than
81% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.09 vs. NYSE:GSK: 0.25 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:GSK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.6 Max: N/A
Current: 0.25
Equity-to-Asset 0.03
NYSE:GSK's Equity-to-Asset is ranked lower than
97% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. NYSE:GSK: 0.03 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:GSK' s Equity-to-Asset Range Over the Past 10 Years
Min: 0  Med: 0.25 Max: 0.67
Current: 0.03
0
0.67
Interest Coverage 5.03
NYSE:GSK's Interest Coverage is ranked lower than
85% of the 635 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 105.95 vs. NYSE:GSK: 5.03 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:GSK' s Interest Coverage Range Over the Past 10 Years
Min: 3.71  Med: 9.74 Max: 17.51
Current: 5.03
3.71
17.51
Piotroski F-Score: 7
Altman Z-Score: 1.37
Beneish M-Score: -2.81
WACC vs ROIC
7.75%
13.49%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 12.37
NYSE:GSK's Operating Margin % is ranked higher than
53% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.42 vs. NYSE:GSK: 12.37 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:GSK' s Operating Margin % Range Over the Past 10 Years
Min: 9.32  Med: 27.93 Max: 43.15
Current: 12.37
9.32
43.15
Net Margin % 5.77
NYSE:GSK's Net Margin % is ranked lower than
62% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.16 vs. NYSE:GSK: 5.77 )
Ranked among companies with meaningful Net Margin % only.
NYSE:GSK' s Net Margin % Range Over the Past 10 Years
Min: 3.27  Med: 18.96 Max: 35.2
Current: 5.77
3.27
35.2
ROE % 131.80
NYSE:GSK's ROE % is ranked higher than
96% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. NYSE:GSK: 131.80 )
Ranked among companies with meaningful ROE % only.
NYSE:GSK' s ROE % Range Over the Past 10 Years
Min: 17.3  Med: 58.26 Max: 179.63
Current: 131.8
17.3
179.63
ROA % 2.90
NYSE:GSK's ROA % is ranked lower than
62% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. NYSE:GSK: 2.90 )
Ranked among companies with meaningful ROA % only.
NYSE:GSK' s ROA % Range Over the Past 10 Years
Min: 1.62  Med: 12.76 Max: 18.45
Current: 2.9
1.62
18.45
ROC (Joel Greenblatt) % 34.24
NYSE:GSK's ROC (Joel Greenblatt) % is ranked higher than
67% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.40 vs. NYSE:GSK: 34.24 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:GSK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 25.79  Med: 83.7 Max: 120.14
Current: 34.24
25.79
120.14
3-Year Revenue Growth Rate 1.80
NYSE:GSK's 3-Year Revenue Growth Rate is ranked lower than
65% of the 607 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.70 vs. NYSE:GSK: 1.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:GSK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -7.7  Med: 4.8 Max: 18.9
Current: 1.8
-7.7
18.9
3-Year EBITDA Growth Rate -20.50
NYSE:GSK's 3-Year EBITDA Growth Rate is ranked lower than
87% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.40 vs. NYSE:GSK: -20.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:GSK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -20.5  Med: 7.9 Max: 21.7
Current: -20.5
-20.5
21.7
3-Year EPS without NRI Growth Rate -44.80
NYSE:GSK's 3-Year EPS without NRI Growth Rate is ranked lower than
94% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. NYSE:GSK: -44.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:GSK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -44.8  Med: 7.4 Max: 51.3
Current: -44.8
-44.8
51.3
GuruFocus has detected 5 Warning Signs with GlaxoSmithKline PLC $NYSE:GSK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:GSK's 30-Y Financials

Financials (Next Earnings Date: 2017-07-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

GSK Guru Trades in Q2 2016

NWQ Managers 2,075,187 sh (+316.61%)
Kahn Brothers 380,335 sh (+188.24%)
Jeremy Grantham 154,880 sh (+93.84%)
Jim Simons 510,800 sh (+6.28%)
John Rogers 1,607,697 sh (+1.57%)
Ken Fisher 11,730,875 sh (+0.63%)
Tweedy Browne 116,491 sh (+0.36%)
Barrow, Hanley, Mewhinney & Strauss 251,800 sh (unchged)
First Eagle Investment 1 sh (unchged)
Diamond Hill Capital 151,307 sh (unchged)
Francis Chou 18,000 sh (unchged)
Murray Stahl 25,973 sh (unchged)
Lee Ainslie Sold Out
PRIMECAP Management 1,115,985 sh (-0.08%)
Jeff Auxier 110,732 sh (-0.49%)
Pioneer Investments 543,125 sh (-1.52%)
HOTCHKIS & WILEY 8,439,389 sh (-5.34%)
Charles Brandes 4,224,506 sh (-5.59%)
Sarah Ketterer 329,801 sh (-26.78%)
Dodge & Cox 44,262 sh (-45.53%)
Joel Greenblatt 25,857 sh (-49.63%)
» More
Q3 2016

GSK Guru Trades in Q3 2016

John Hussman 50,000 sh (New)
Jeremy Grantham 1,563,336 sh (+909.39%)
Jim Simons 930,000 sh (+82.07%)
Kahn Brothers 632,040 sh (+66.18%)
NWQ Managers 2,658,155 sh (+28.09%)
Ken Fisher 11,861,172 sh (+1.11%)
Francis Chou 18,000 sh (unchged)
First Eagle Investment 1 sh (unchged)
Diamond Hill Capital 151,307 sh (unchged)
John Rogers 1,607,697 sh (unchged)
Murray Stahl 25,973 sh (unchged)
Pioneer Investments 542,025 sh (-0.20%)
PRIMECAP Management 1,109,085 sh (-0.62%)
Sarah Ketterer 327,419 sh (-0.72%)
Tweedy Browne 114,844 sh (-1.41%)
Joel Greenblatt 25,284 sh (-2.22%)
HOTCHKIS & WILEY 8,150,402 sh (-3.42%)
Jeff Auxier 105,772 sh (-4.48%)
Dodge & Cox 41,962 sh (-5.20%)
Barrow, Hanley, Mewhinney & Strauss 235,200 sh (-6.59%)
Charles Brandes 3,525,668 sh (-16.54%)
» More
Q4 2016

GSK Guru Trades in Q4 2016

John Paulson 296,000 sh (New)
Jim Simons 3,085,500 sh (+231.77%)
Kahn Brothers 833,315 sh (+31.85%)
Jeremy Grantham 1,820,174 sh (+16.43%)
Joel Greenblatt 26,315 sh (+4.08%)
John Rogers 1,646,146 sh (+2.39%)
Pioneer Investments 545,625 sh (+0.66%)
First Eagle Investment 1 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss 235,200 sh (unchged)
Diamond Hill Capital 151,307 sh (unchged)
Francis Chou 18,000 sh (unchged)
John Hussman Sold Out
Tweedy Browne 114,437 sh (-0.35%)
Ken Fisher 11,809,500 sh (-0.44%)
PRIMECAP Management 1,093,985 sh (-1.36%)
NWQ Managers 2,568,013 sh (-3.39%)
HOTCHKIS & WILEY 7,807,200 sh (-4.21%)
Murray Stahl 23,973 sh (-7.70%)
Sarah Ketterer 294,560 sh (-10.04%)
Charles Brandes 3,149,621 sh (-10.67%)
Dodge & Cox 36,762 sh (-12.39%)
Jeff Auxier 89,247 sh (-15.62%)
» More
Q1 2017

GSK Guru Trades in Q1 2017

Jim Simons 4,402,100 sh (+42.67%)
John Paulson 415,100 sh (+40.24%)
Kahn Brothers 1,050,995 sh (+26.12%)
Diamond Hill Capital 190,052 sh (+25.61%)
Sarah Ketterer 315,515 sh (+7.11%)
Charles Brandes 3,363,788 sh (+6.80%)
Ken Fisher 11,969,866 sh (+1.36%)
Murray Stahl 24,073 sh (+0.42%)
NWQ Managers 2,568,415 sh (+0.02%)
First Eagle Investment 1 sh (unchged)
John Rogers 1,646,146 sh (unchged)
PRIMECAP Management 1,093,985 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss 235,200 sh (unchged)
Francis Chou Sold Out
Pioneer Investments 541,525 sh (-0.75%)
Jeff Auxier 88,147 sh (-1.23%)
Tweedy Browne 110,579 sh (-3.37%)
Joel Greenblatt 25,392 sh (-3.51%)
HOTCHKIS & WILEY 7,524,627 sh (-3.62%)
Dodge & Cox 32,187 sh (-12.44%)
Jeremy Grantham 610,400 sh (-66.46%)
» More
» Details

Insider Trades

Latest Guru Trades with GSK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:ABBV, OTCPK:BAYRY, NYSE:BMY, NYSE:LLY, NYSE:AZN, NYSE:SNY, NYSE:MRK, OTCPK:ALPMF, OTCPK:OTSKY, OTCPK:CHGCY, NYSE:NVS, NYSE:PFE, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHPTY, OTCPK:PTKFY, OTCPK:SNPHY, OTCPK:GWPRF, NAS:HCM » details
Traded in other countries:GSK.Argentina, GS7.Germany, GSK N.Mexico, GSK.Switzerland, GSK.UK, GLAXF.USA,
Headquarter Location:UK
GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across multiple therapeutic classes, including respiratory and antiviral, as well as vaccines and healthcare-related consumer products.

Guru Investment Theses on GlaxoSmithKline PLC

Ariel Funds Comments on GlaxoSmithKline plc - Sep 28, 2016

In addition, GlaxoSmithKline plc (NYSE:GSK) rallied +7.74%1 in the second quarter, after reporting profit growth for the first time since 2013. Glaxo is seeing benefits from its purchase of Novartis’ vaccines unit. Demand for vaccines and new drugs helped offset declines in the sales of blockbuster asthma medication Advair.

From John Rogers (Trades, Portfolio)' second quarter 2016 Ariel Global Fund commentary.

Check out John Rogers latest stock trades

Top Ranked Articles about GlaxoSmithKline PLC

GlaxoSmithKline, Vodafone Hit 3-Year Low Prices 4 stocks that present opportunities to buy
GlaxoSmithKline PLC (NYSE:GSK), Diageo PLC (NYSE:DEO), Vodafone Group PLC (NASDAQ:VOD) and National Grid PLC (NYSE:NGG) have reached their three-year low prices. Read more...
Kahn Brothers Adds to 4 Holdings in 3rd Quarter Largest acquisition is in GlaxoSmithKline
Kahn Brothers (Trades, Portfolio) added to four holdings in its portfolio in the third quarter. Read more...
Novartis Is Surviving Restructuring leads to promising future business developments
On July 19, the $188 billion Swiss multinational pharmaceutical company delivered its first half fiscal year 2016 results. The company delivered constant currency sales and profit growth of 1% to $24 billion and -2% to $3.8 billion, respectively. Novartis (NYSE:NVS) shares closed -0.62% that day, while the broader S&P 500 index closed -0.14%. Read more...
Strong Revenue Points to Gains at GlaxoSmithKline Business purchases could be key revenue generators
In the biotech arena, there are few names that attract as much attention as GlaxoSmithKline PLC (NYSE:GSK), which closed at $43.42 on Sept. 23, 2016 (down by 0.37 percent from the previous close). The stock has gyrated in a 52-week range between $37.24 and $45.58, which indicates that valuations are currently at the bullish end of the spectrum. Read more...
Ariel Funds Comments on GlaxoSmithKline plc Guru stock highlight
In addition, GlaxoSmithKline plc (NYSE:GSK) rallied +7.74%1 in the second quarter, after reporting profit growth for the first time since 2013. Glaxo is seeing benefits from its purchase of Novartis’ vaccines unit. Demand for vaccines and new drugs helped offset declines in the sales of blockbuster asthma medication Advair. Read more...
Regulatory Update on US Filing Plans for Closed Triple Combination Therapy FF/UMEC/VI in Patients With COPD

Acceleration of Filing of US New Drug Application Now Expected by End of 2016

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 2, 2016) - GlaxoSmithKline plc (LSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that, following discussions with the US Food and Drug Administration (FDA), GSK has brought forward the plan to file a New Drug Application (NDA) in the US for the once-daily closed triple combination therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; a combination inhaled corticosteroid, long-acting muscarinic antagonist, long-acting beta agonist) for patients with chronic obstructive pulmonary disease (COPD). The US regulatory submission is now anticipated by the end of 2016, rather than the first half of 2018, as previously expected. The NDA for the closed triple combination therapy will comprise data now in hand from the closed triple combination therapy development programme, as well as data from studies with FF, UMEC and VI either alone or in combination. The companies continue to expect an EU regulatory submission of the closed triple combination therapy for COPD by the end of 2016. About closed triple therapy

The closed triple therapy is a combination of three molecules: fluticasone furoate (FF), an inhaled corticosteroid (ICS), umeclidinium (UMEC), an anti-cholinergic, also known as a long-acting muscarinic antagonist (LAMA) and vilanterol (VI), a long-acting beta2-adrenergic agonist (LABA) delivered once-daily in GSK's Ellipta® dry powder inhaler. About the ongoing clinical programme in COPD

The ongoing clinical programme in patients with COPD comprises two studies investigating the effectiveness and safety of closed triple therapy compared to existing COPD treatments.

The FULFIL (Lung FUnction and quality of LiFe assessment in COPD with closed trIpLe therapy) study, which began in 2015 and is expected to read out later in 2016 to support EU filing, is assessing whether the closed triple therapy can improve lung function and health-related quality of life compared with Symbicort® (budesonide/formoterol), a twice-daily ICS/LABA combination delivered via the Turbohaler® inhaler.



The IMPACT (InforMing the PAthway of COPD Treatment) study, which began in 2014 and is expected to read out in 2017, is investigating whether FF/UMEC/VI can reduce the rate of exacerbations compared with two, once-daily dual therapies from GSK's existing portfolio: FF/VI, an ICS/LABA combination and UMEC/VI, a LAMA/LABA combination.

The closed triple combination of FF/UMEC/VI is not approved for use anywhere in the world. GSK -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com. Innoviva - Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (NYSE:GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance Biopharma, Inc., including the closed triple combination therapy for COPD. For more information, please visit Innoviva's website at www.inva.com. RELVAR®, BREO®, ANORO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies. SYMBICORT® and TURBOHALER® are trademarks of AstraZeneca. GSK cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2015. Innoviva forward-looking statements

This press release contains certain "forward-looking" statements. Such forward-looking statements involve substantial risks, uncertainties and assumptions. Examples of such statements include statements relating to: the development, regulatory and commercial plans for closed triple combination therapy, the commercialization of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® in the jurisdictions in which these products have been approved; the strategies, plans and objectives of the company (including the company's growth strategy and corporate development initiatives beyond the existing respiratory portfolio); the timing, manner, amount and planned growth of anticipated potential capital returns to stockholders (including, without limitation, statements regarding the company's expectations of future share purchases and future cash dividends); the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; projections of revenue, expenses and other financial items; and risks related to the implementation of our share repurchase program as currently contemplated. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: lower than expected future royalty revenue from respiratory products partnered with GSK, delays or difficulties in commencing or completing clinical studies, the potential that results from clinical or non-clinical studies indicate product candidates are unsafe or ineffective, dependence on third parties to conduct its clinical studies, delays or failure to achieve and maintain regulatory approvals for product candidates, and risks of collaborating with third parties to discover, develop and commercialize products. Other risks affecting Innoviva are described under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" contained in Innoviva's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov. Additional information will also be set forth in those sections of Innoviva's Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, which will be filed with the SEC in the third quarter of 2016. In addition to the risks described above and in Innoviva's other filings with the SEC, other unknown or unpredictable factors also could affect Innoviva's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law. Registered in England & Wales:

No. 3888792 Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS


GSK enquiries:


UK Media enquiries:

David Mawdsley

44 (0) 20 8047 5502

(London)


Simon Steel

44 (0) 20 8047 5502

(London)


David Daley

44 (0) 20 8047 5502

(London)


Sarah Macleod

44 (0) 20 8047 5502

(London)


US Media enquiries:

Sarah Alspach

1 202 715 1048

(Washington, DC)


Sarah Spencer

1 215 751 3335

(Philadelphia)


Karen Hagens

1 919 483 2863

(North Carolina)


Analyst/Investor enquiries:

Ziba Shamsi

44 (0) 20 8047 5543

(London)


Tom Curry

1 215 751 5419

(Philadelphia)


Gary Davies

44 (0) 20 8047 5503

(London)


James Dodwell

44 (0) 20 8047 2406

(London)


Jeff McLaughlin

1 215 751 7002

(Philadelphia)


Innoviva, Inc. enquiries:


Investor Relations:

Eric d'Esparbes

1 (650) 238-9605

[email protected]

South San Francisco, CA





Read more...

Ratios

vs
industry
vs
history
PE Ratio 47.63
GSK's PE Ratio is ranked lower than
86% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.48 vs. GSK: 47.63 )
Ranked among companies with meaningful PE Ratio only.
GSK' s PE Ratio Range Over the Past 10 Years
Min: 6.35  Med: 14.72 Max: 99999999.99
Current: 47.63
6.35
99999999.99
Forward PE Ratio 15.24
GSK's Forward PE Ratio is ranked higher than
99% of the 202 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.39 vs. GSK: 15.24 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 47.63
GSK's PE Ratio without NRI is ranked lower than
87% of the 544 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.85 vs. GSK: 47.63 )
Ranked among companies with meaningful PE Ratio without NRI only.
GSK' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.38  Med: 14.65 Max: 284.83
Current: 47.63
6.38
284.83
Price-to-Owner-Earnings 15.25
GSK's Price-to-Owner-Earnings is ranked higher than
81% of the 293 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.45 vs. GSK: 15.25 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GSK' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.81  Med: 15.53 Max: 125.21
Current: 15.25
4.81
125.21
PB Ratio 46.39
GSK's PB Ratio is ranked lower than
99% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.03 vs. GSK: 46.39 )
Ranked among companies with meaningful PB Ratio only.
GSK' s PB Ratio Range Over the Past 10 Years
Min: 5.48  Med: 9.35 Max: 610.36
Current: 46.39
5.48
610.36
PS Ratio 2.75
GSK's PS Ratio is ranked higher than
51% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. GSK: 2.75 )
Ranked among companies with meaningful PS Ratio only.
GSK' s PS Ratio Range Over the Past 10 Years
Min: 1.94  Med: 2.78 Max: 3.84
Current: 2.75
1.94
3.84
Price-to-Free-Cash-Flow 15.99
GSK's Price-to-Free-Cash-Flow is ranked higher than
59% of the 226 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.83 vs. GSK: 15.99 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GSK' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.24  Med: 16.69 Max: 136.91
Current: 15.99
8.24
136.91
Price-to-Operating-Cash-Flow 11.16
GSK's Price-to-Operating-Cash-Flow is ranked higher than
65% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.62 vs. GSK: 11.16 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GSK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.62  Med: 11.85 Max: 27.46
Current: 11.16
6.62
27.46
EV-to-EBIT 26.69
GSK's EV-to-EBIT is ranked higher than
89% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.99 vs. GSK: 26.69 )
Ranked among companies with meaningful EV-to-EBIT only.
GSK' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.3  Med: 10.7 Max: 72.6
Current: 26.69
6.3
72.6
EV-to-EBITDA 18.74
GSK's EV-to-EBITDA is ranked higher than
95% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.26 vs. GSK: 18.74 )
Ranked among companies with meaningful EV-to-EBITDA only.
GSK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.6  Med: 9.2 Max: 35.2
Current: 18.74
5.6
35.2
Shiller PE Ratio 17.32
GSK's Shiller PE Ratio is ranked higher than
88% of the 161 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.67 vs. GSK: 17.32 )
Ranked among companies with meaningful Shiller PE Ratio only.
GSK' s Shiller PE Ratio Range Over the Past 10 Years
Min: 11.71  Med: 15.15 Max: 20.81
Current: 17.32
11.71
20.81
Current Ratio 0.89
GSK's Current Ratio is ranked lower than
91% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.55 vs. GSK: 0.89 )
Ranked among companies with meaningful Current Ratio only.
GSK' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 1.3 Max: 2.64
Current: 0.89
0.88
2.64
Quick Ratio 0.61
GSK's Quick Ratio is ranked lower than
91% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.85 vs. GSK: 0.61 )
Ranked among companies with meaningful Quick Ratio only.
GSK' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.01 Max: 2.24
Current: 0.61
0.61
2.24
Days Inventory 200.23
GSK's Days Inventory is ranked lower than
83% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.29 vs. GSK: 200.23 )
Ranked among companies with meaningful Days Inventory only.
GSK' s Days Inventory Range Over the Past 10 Years
Min: 167.28  Med: 188.56 Max: 202.64
Current: 200.23
167.28
202.64
Days Sales Outstanding 81.07
GSK's Days Sales Outstanding is ranked higher than
63% of the 636 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.05 vs. GSK: 81.07 )
Ranked among companies with meaningful Days Sales Outstanding only.
GSK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.62  Med: 59.8 Max: 93.9
Current: 81.07
54.62
93.9
Days Payable 135.73
GSK's Days Payable is ranked higher than
82% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.53 vs. GSK: 135.73 )
Ranked among companies with meaningful Days Payable only.
GSK' s Days Payable Range Over the Past 10 Years
Min: 98.94  Med: 133.85 Max: 345.65
Current: 135.73
98.94
345.65

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 4.67
GSK's Dividend Yield % is ranked higher than
97% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. GSK: 4.67 )
Ranked among companies with meaningful Dividend Yield % only.
GSK' s Dividend Yield % Range Over the Past 10 Years
Min: 2.92  Med: 5.12 Max: 6.24
Current: 4.67
2.92
6.24
Dividend Payout Ratio 2.26
GSK's Dividend Payout Ratio is ranked higher than
64% of the 410 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. GSK: 2.26 )
Ranked among companies with meaningful Dividend Payout Ratio only.
GSK' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.46  Med: 0.75 Max: 4.3
Current: 2.26
0.46
4.3
3-Year Dividend Growth Rate -1.30
GSK's 3-Year Dividend Growth Rate is ranked lower than
68% of the 285 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. GSK: -1.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
GSK' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5 Max: 62.4
Current: -1.3
0
62.4
Forward Dividend Yield % 4.59
GSK's Forward Dividend Yield % is ranked higher than
97% of the 658 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.59 vs. GSK: 4.59 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.86
GSK's 5-Year Yield-on-Cost % is ranked higher than
88% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.09 vs. GSK: 4.86 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
GSK' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 3.04  Med: 5.33 Max: 6.49
Current: 4.86
3.04
6.49
3-Year Average Share Buyback Ratio -0.40
GSK's 3-Year Average Share Buyback Ratio is ranked higher than
55% of the 442 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. GSK: -0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GSK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.7  Med: -0.5 Max: 4.7
Current: -0.4
-26.7
4.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.24
GSK's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
53% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. GSK: 2.24 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GSK' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.96  Med: 1.94 Max: 70.18
Current: 2.24
0.96
70.18
Price-to-Median-PS-Value 0.98
GSK's Price-to-Median-PS-Value is ranked higher than
57% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. GSK: 0.98 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GSK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.62  Med: 1.18 Max: 3.35
Current: 0.98
0.62
3.35
Earnings Yield (Greenblatt) % 3.74
GSK's Earnings Yield (Greenblatt) % is ranked higher than
92% of the 1046 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.36 vs. GSK: 3.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GSK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.4  Med: 9.4 Max: 15.8
Current: 3.74
1.4
15.8
Forward Rate of Return (Yacktman) % -8.72
GSK's Forward Rate of Return (Yacktman) % is ranked lower than
84% of the 369 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.72 vs. GSK: -8.72 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
GSK' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -8.9  Med: 8.9 Max: 18.2
Current: -8.72
-8.9
18.2

More Statistics

Revenue (TTM) (Mil) $37,776
EPS (TTM) $ 0.83
Beta1.03
Short Percentage of Float0.00%
52-Week Range $37.20 - 45.58
Shares Outstanding (Mil)2,459.00

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 38,382 39,541 40,625
EPS ($) 2.80 2.87 3.13
EPS without NRI ($) 2.80 2.87 3.13
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.49%
Dividends per Share ($) 2.07 2.07 2.07
» More Articles for NYSE:GSK

Headlines

Articles On GuruFocus.com
Seth Klarman Backs Out of Innoviva Days After Activist Stakeholder Defeated May 10 2017 
Pernix: An Investor's Rationale to Staying Long Mar 23 2017 
Jeff Auxier Reduces, Exits Multiple Positions in 4th Quarter Mar 22 2017 
Gilead Sciences Raises Dividend by Double Digits Feb 22 2017 
If You Want Yield, Look to the UK Feb 19 2017 
Flood of News Presents Buying Opportunity Jan 17 2017 
Gilead Sciences Must Answer to Investors After a Disappointing 2016 Jan 05 2017 
GlaxoSmithKline, Vodafone Hit 3-Year Low Prices Dec 24 2016 
Asset Sales, New Projects Fuel 6.7% Yield Dec 07 2016 
Robust Pipeline Supports 5.5% Dividend Yield Dec 05 2016 

More From Other Websites
Top Analyst Reports for Visa, GE, GlaxoSmithKline & Others May 26 2017
GlaxoSmithKline's New CEO Is Off to a Good Start May 26 2017
Gardasil and Merck’s Vaccines Business in 1Q17 May 24 2017
A Close Look at Merck & Co.’s Valuation after 1Q17 Earnings May 23 2017
Better Buy: Celldex Therapeutics, Inc. vs. Agenus Inc. May 21 2017
Ionis (IONS) Stock Falls Despite Positive Inotersen Data May 16 2017
Citi Prefers These 4 Stocks Over Pfizer On Bottom-Line Concerns May 16 2017
Today's Research Reports on Stocks to Watch: GlaxoSmithKline and Novartis May 16 2017
GlaxoSmithKline Could Buy Out Partner Novartis May 15 2017
Top-10 Glaxo investor Woodford sells out, criticises board May 12 2017
Glaxit: GlaxoSmithKline Sees a Top Investor Dump Stock out of 'Frustration' May 12 2017
Woodford Turns Bullish on Lloyds as He Cuts Ties With Glaxo May 12 2017
Hikma Shares Plunge After It Says 'Low Likelihood' of 2017 Generic Advair Approval May 11 2017
Mylan disagrees with FDA over generic Advair delay May 10 2017
GlaxoSmithKline Plc : GSK-US: Dividend Analysis : May 12th, 2017 (record date) : By the numbers :... May 10 2017
Better Buy: GlaxoSmithKline vs. Johnson & Johnson May 10 2017
Which Big Pharma Is the Best Dividend Stock? May 06 2017
GSK 'real world' drug test has second success in asthma May 05 2017
Relvar Ellipta Significantly Improved Asthma Control in Salford Lung Study Patients Compared with... May 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)